LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
June 10, 2024 08:00 ET | LENZ Therapeutics, Inc.
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 ...
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024 08:00 ET | LENZ Therapeutics, Inc.
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 08, 2024 16:01 ET | LENZ Therapeutics, Inc.
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3...
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
May 01, 2024 16:01 ET | Lenz Therapeutics, Inc.
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...